Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.57 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.57 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.54 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.54 |
| ▸ | AMY2A | P04746 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383063 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29510709 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL12871588 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL30943987 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL31154034 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29407248 | 0.99 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL30532206 | 0.98 | LGALS3 (0.57) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29367524 | 0.98 | LGALS3 (0.57) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29737501 | 0.98 | LGALS3 (0.57) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29665054 | 0.98 | LGALS3 (0.57) | LGALS3LGALS8LGALS4CD209ENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250325-A1 | Methods of Manufacturing Alpha-1 Antitrypsin Compositions For Treatment of Disease Disorders | LEZDEY DARREN (US) | 2025-08-07 | — | — | US | claimed |
| CN-118515765-A | Glycosylated CD47 nanobody, extracellular vesicle, preparation method and application thereof | 深圳湾实验室 | 2024-08-20 | — | — | CN | claimed |
| EP-3205351-B1 | LYSOSOMAL STORAGE DISEASE ENZYME | ALEXION PHARMA INC (US) | 2023-04-12 | — | — | EP | claimed |
| EP-4748446-A2 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125467-A1 | NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS | IMMUNE ONC THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731235-A1 | COMPOSITION | Kyron.bio SAS (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-12596122-B2 | LILRB2 antibodies and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-07 | — | — | US | disclosed |
| US-12559555-B2 | Anti-LILRB4 antibodies and derivative products | IMMUNE-ONC THERAPEUTICS, INC. | 2026-02-24 | — | — | US | disclosed |
| US-12545733-B2 | Anti-CD103 antibodies | IMMIOS HOLDING B.V. (NL) | 2026-02-10 | — | — | US | disclosed |
| EP-3445393-B1 | CMV NEUTRALIZING ANTIGEN BINDING PROTEINS | MERCK SHARP & DOHME LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388654-A1 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4003523-A1 | ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES | Merck Sharp & Dohme Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220145311-A1 | PICHIA PASTORIS STRAINS FOR PRODUCING PREDOMINANTLY HOMOGENEOUS GLYCAN STRUCTURE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220135677-A1 | ANTI-SIRP ALPHA ANTIBODIES | SAIROPA B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| US-20220135671-A1 | ANTI-SIRP ALPHA ANTIBODIES | ADURO BIOTECH HOLDINGS, EUROPE B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| WO-2022087188-A1 | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVATIVE PRODUCTS | IMMUNE-ONC THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220110871-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| US-11278620-B2 | Anti-LAG3 antibodies and antigen-binding fragments | MERCK SHARP & DOHME CORP. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3954360-A2 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | Glycomine, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022026360-A2 | MONOCLONAL ANTIBODIES AGAINST LILRB1 FOR DIAGNOSTIC AND THERAPEUTIC USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12596122-B2 | LILRB2 antibodies and uses thereof | FCGR3B, IL2RA, LIFR | LGALS3 921/4885LGALS8 1939/4885LGALS4 2092/4885 |
| US-20220135671-A1 | ANTI-SIRP ALPHA ANTIBODIES | NASP, STAMBP, SIRT6 | LGALS3 2558/4885LGALS8 2753/4885LGALS4 2868/4885 |
| US-20260125467-A1 | NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS | FCGR3B, IGLV6-57, IGSF11 | LGALS3 1814/4885LGALS8 2000/4885LGALS4 851/4885 |
| US-20220135677-A1 | ANTI-SIRP ALPHA ANTIBODIES | NASP, STAMBP, SIRT6 | LGALS3 2558/4885LGALS8 2753/4885LGALS4 2868/4885 |
| US-12559555-B2 | Anti-LILRB4 antibodies and derivative products | LIFR, IL2RA, IGSF11 | LGALS3 332/4885LGALS8 1254/4885LGALS4 500/4885 |
| US-12545733-B2 | Anti-CD103 antibodies | CD74, CD99, MALT1 | LGALS3 1080/4885LGALS8 2896/4885LGALS4 1878/4885 |
| US-20250388654-A1 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | IGLV6-57, VSIG8, IGSF11 | LGALS3 1119/4885LGALS8 2349/4885LGALS4 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.